Antineoplastic agents 1998

Bibliography

• DRANOFF G: Cancer gene therapy: connecting basic re- search with clinical inquiry. J. Gun. Oncol. (1998) 16:2548–2556.
   Google Scholar
• DIMITROFF CJ, SHARMA A, BERNACKI RJ: Cancer metas-tasis: a search for therapeutic inhibition. Cancer. Invest. (1998) 16:279–290.
   PubMed Web of Science ®Google Scholar
• MENTA E, PALUMBO M: Novel antineoplastic agents. Exp. Opin. Ther. Patents (1997) 7:1401–1426.
   Web of Science ®Google Scholar
• LOKICH J, ANDERSON N: Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. On-col. (1998) 9:13–21.
   Google Scholar
• MALONNE H, ATASSI G: DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anti-cancer Drugs (1997) 8:811–822.
   PubMed Web of Science ®Google Scholar
• ZAGOTTO G, MORO S, URIARTE E et al: Amido analogs of mitoxantrone: physico-chemical properties, mo-lecular modeling, cellular effects and antineoplastic potential. Anticancer Drug Des. (1997) 12:99–112.
   PubMedGoogle Scholar
• HUSAIN I, MOHLER JL, SEIGLER HF et al: Elevation of to-poisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemo-therapy. Cancer Res. (1994) 54:539–546.
   PubMed Web of Science ®Google Scholar
• SCHELLENS JH, PRONK LC, VERWEIJ JAD: Emerging drug treatments for solid tumours. Drugs (1996) 51:45–72.
   PubMedGoogle Scholar
• HARTLEY JA, LOWN JW, MATTES WB et al.: DNA se-quence specificity of antitumor agents. Oncogenes as possible targets for cancer therapy. Acta Oncol (1988) 27:503–510.
   Google Scholar
• FILIPPINI C, BISIACH M, TAGLIABUE G et al: Hemato-poietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agents. Int. J. Cancer (1997) 72:801–809.
   PubMedGoogle Scholar
• PHILLIPS RM: Bioreductive activation of a series of ana- logues of 5-aziridiny1-3-hydroxymethy1-1-methyl-241H-indole-4,7-dionelprop- p-en-a-ol MOW by human DT-diaphorase. Biochem. Pharmacol. (1996) 52:1711–1718.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY TJ, GOMER CJ, HENDERSON BW eta].: Pho-todynamic therapy. J. Natl. Cancer. Inst. (1998) 90:889–905.
   PubMed Web of Science ®Google Scholar
• OCHSNER M: Photodynamic therapy: the clinical per-spective. Review on applications for control of diverse tumorous and non-tumorous diseases. Arzneimittel-forsch. (1997) 47:1185–1194.
   Google Scholar
• TER HAAR E: Taxanes and other microtubule stabilis-ing agents. Exp. Opin. Ther. Patents (1998) 8:571–586.
   Web of Science ®Google Scholar
• SMITH CD, ZHANG X, MOOBERRY SL et al: Cryptophi-cyn: a new antimicrotubule agent active against drug resistant cells. Cancer Res. (1994) 54:3779–3784.
   PubMed Web of Science ®Google Scholar
• PANDA D, HIMES RH, MOORE RE et al: Mechanism of ac-tion of the unusually potent microtubule inhibitor cryptophycin 1. Biochemistry (1997) 36:12948–12953.
   PubMed Web of Science ®Google Scholar
• MOOBERRY SL, BUSQUETS L, TIEN G: Induction of apop-tosis by cryptophycin 1, a new antimicrotubule agent. Int. J. Cancer (1997) 73:440–448.
   PubMed Web of Science ®Google Scholar
• DIXON SC, ARAH IN: Apoptosis: a novel therapeutic tool? Exp. Opin. Invest. Drugs (1998) 7:889–904.
   Google Scholar
• HAMILTON SE, COREY DR: Telomerase: anti-cancer tar-get or just a fascinating enzyme? Chem. Biol. (1996) 3:863–867.
   Google Scholar
• SHAY JW: Telomerase in cancer: diagnostic, prognos-tic, and therapeutic implications. Cancer J. Sci. Am. (1998) 4:S26–S34.
   Google Scholar
• BRIDGES A, ZHOU H, CODY DR eta].: Tyrosine kinase inhibitors. 8. An unusually steep structure activity re-lationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibi-tor of the epidermal growth factor receptor. J. Med. Chem. (1996) 39:267–276.
   Google Scholar
• THOMPSON AM, MURRAY DK, ELLIOT WL et al.: Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted-4-[(3-bromophenyfiamino] pyrido[4,3-olpyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Merl. Chem. (1997) 40:3915–3925.
   Google Scholar
• TRAXLER PM, FURET P, METT H et al.: 4- (P hen-ylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor pro-tein tyrosine kinase. j Med. Chem. (1996) 39:2285–2292.
   PubMed Web of Science ®Google Scholar
• TRAXLER P, BOLD G, FREI J et al: Use of a pharma-cophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-ol pyrimid-ines. j Med. Chem. (1997) 40:3601–3616.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT CA, KAMPS MP, MEISLER Al et al: pp60c-src activation in human colon carcinoma. J. Clin. Invest. (1989) 83:2025–2033.
   PubMed Web of Science ®Google Scholar
• DENNY WA, SMAILL JB, FRY DW et al.: Structure-activity relationships for 4-anilinoquinazoline and related pyridopyrirmidine acrylamides as specific irreversi-ble inhibitors of the epidermal growth factor receptor. Proc. Am. Assoc. Cancer Res. (1998) 39:559. Abstract 3804.
   Google Scholar
• PATMORE SJ, ROBERTS BJ,. STONER CL et al: In vivo evaluation of the irreversible EGF receptor tyrosine ki-nase inhibitor PD 168393. Proc. Am. Assoc. Cancer Res. (1998) 39:560. Abstract 3805.
   Google Scholar
• FRY DW, NELSON JM, SLINTAK V et al: Specific, irre-versible inhibitors of the epidermal growth factor re-ceptor (EGFR) family of tyrosine kinases. Proc. Am. Assoc. Cancer Res. (1998) 39:560. Abstract 3806.
   Google Scholar
• VINCENT PW, AKINSON BE, ZHOU H eta].: Characteriza-tion of the in vivo activity of a novel EGF receptor fam-ily kinase inhibitor, PD 169414. Proc. Am. Assoc. Cancer Res. (1998) 39:560. Abstract 3807.
   Google Scholar
• SUN L, TRAN N, TANG F et al: Synthesis and biological evaluation of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectiv-ity toward particular receptor tyrosine kinases. J. Med. Chem. (1998) 41:2588–2603.
   PubMed Web of Science ®Google Scholar
• O'BRIAN CA, WARD NE: Biology of the protein kinase C family. Cancer Metastasis Rev. (1989) 8:199–214.
   PubMed Web of Science ®Google Scholar
• CLOUD-HEFLIN BA, MCMASTERS RA, OSBORN MT et al.: Expression, subcellular distribution and response to phorbol esters of protein kinase C (PKC) isozymes in drug-sensitive and multidrug-resistant KB cells evi-dence for altered regulation of PKC-alpha. Eur. J. Bio-chem. (1996) 239:796–804.
   Google Scholar
• CAPONIGRO F, FRENCH RC, KAYE SB: Protein kinase C: a worthwhile target for anticancer drugs? Anticancer Drugs (1997) 8:26–33.
   PubMed Web of Science ®Google Scholar
• LENTZ SS: Endocrine therapy of endometrial cancer. Cancer Treat. Res. (1998) 94:89–106.
   PubMedGoogle Scholar
• NICKEL JC: Long-term implications of medical therapy on benign prostatic hyperplasia end points. Urology (1998) 51:50–57.
   PubMedGoogle Scholar
• BUZDAR AU, HORTOBAGYI G: Update on endocrine therapy for breast cancer. Clin. Cancer Res. (1998) 4:527–534.
   PubMed Web of Science ®Google Scholar
• WADKINS RM, ROEPE PD: Biophysical aspects of P-glycoprotein-mediated multidrug resistance. mt. Rev. Cytol. (1997) 171:121–165.
   PubMedGoogle Scholar
• SIKIC BI, FISHER GA, LUM BL et al.: Modulation and pre-vention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. (1997) 40:S13–19.
   PubMed Web of Science ®Google Scholar
• VOLM M. Multidrug resistance and its reversal. Antican-cer Res. (1998) 18:2905–2917.
   PubMed Web of Science ®Google Scholar
• SARKADI B, MULLER M. Search for specific inhibitors of multidrug resistance in cancer. Semin. Cancer Biol. (1997) 8:171–182.
   PubMed Web of Science ®Google Scholar
• FORD JM, BRUGGEMANN EP, PASTAN I et al.: Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. (1990) 50:1748–1756.
   PubMedGoogle Scholar
• OGINO J, MOORE RE, PATTERSON GM et al.: Den-droamides, new cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing activity of dendroamide A. J. Nat. Prod. (1996) 59:581–586.
   PubMed Web of Science ®Google Scholar
• DUFFY MJ: Cancer metastasis: biological and clinical aspects. Jr. J. Med. Sci. (1998) 167:4–8.
   Google Scholar
• BARINAGA M: Designing therapies that target tumor blood vessels. Science (1997) 275:482–484.
   PubMedGoogle Scholar
• ZETTER BR: Angiogenesis and tumor metastasis. Ann. Rev. Med. (1998) 49:407–424.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, HOLMGREN L, SHING Y et al: Angiostatin: a novel angiogenesis inhibitor that mediates the sup-pression of metastases by a Lewis lung carcinoma. Cell (1994) 79:315–328.
   PubMed Web of Science ®Google Scholar
• BOEHM T, FOLKMAN J, BROWDER T et al.: Antiangio-genic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390:404–407.
   PubMed Web of Science ®Google Scholar
• HAGMANN WK, BECKER JW: Inhibition of matrix metal-loproteinases. Ann. Rep. Med. Chem. (1996) 31:231–240.
   Google Scholar
• WEIDLE UH, KONIG B: Urokinase receptor antagonists: novel agents for the treatment of cancer. Exp. Opin. In-vest. Drugs (1998) 7:391–403.
   PubMedGoogle Scholar
• RABBANI SA, XING RH: Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. (1998) 12:911–920.
   PubMed Web of Science ®Google Scholar
• POWELL D, SKOTNICKI J, UPESLACIS J: Angiogenesis in-hibitors. Ann. Rep. Med. Chem. (1997) 32:161–170.
   Google Scholar
• BECKETT RP, WHITTAKER M: Matrix metalloprote-inases inhibitor 1998. Exp. Opin. Ther. Patents (1998) 8:259–282.
   Web of Science ®Google Scholar
• FIELDS GB: Integrins: cell adhesion molecules in can-cer. Exp. Opin. Ther. Patents (1998) 8:633–644.
   Google Scholar
• VAJKOCZY P, MENGER MD, VOLLMAR B et al: Effect of the Flk-1 antagonist SU 5416 on tumor growth, angio-genesis and micro-hemodynamics. Proc. Am. Assoc. Cancer Res. (1998) 39:96. Abstract 651.
   Google Scholar
• FONG TAT, SHAWVER LK, APP H et al.: SU 5416: a potent and selective Flk- 1/KDR kinase inhibitor that blocks Flk-1 phosphorylation, endothelial cell mitogenesis, and tumor growth. Proc. Am. Assoc. Cancer Res. (1998) 39:305. Abstract 3811.
   Google Scholar
• 4-Anilinoquinazoline derivatives. Exp. Opin. Ther. Pat-ents (1998) 8:475–478.
   Google Scholar
• MANETTI F, CAPPELLO V, BOTTA M et al.: Synthesis and binding mode of heterocyclic analogues of suramin in-hibiting the human basic fibroblast growth factor. Bioorg. Med. Chem. (1998) 6:947–958.
   PubMedGoogle Scholar
• GRIFFITH EC, SU Z, TURK BE et al.: Methionine amino-peptidase (type 2) is the common target for angiogene-sis inhibitors AGM-1470 and ovalicin. Chem. Biol. 1997 4:461–471.
   PubMed Web of Science ®Google Scholar
• SIN N, MENG L, WANG MQ et al.: The anti-angiogenicagent fumagillin covalently binds and inhibits the me-thionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA (1997) 94:6099–6103.
   PubMed Web of Science ®Google Scholar
• TURK BE, SU Z, LIU JO: Synthetic analogues of TNP-470and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg. Med. Chem. (1998) 6:1163–1169.
   PubMedGoogle Scholar
• FOTSIS T, ZHANG Y, PEPPER MS et al.: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature (1994) 368:237–239.
   PubMed Web of Science ®Google Scholar
• KLAUBER N, PARANGI S, HAMEL E, D'AMATO RJ: Inhibi-tion of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. (1997) 57:81–86.
   PubMed Web of Science ®Google Scholar
• SILLS AK JR, WILLIAMS JI, TYLER BM etal.: Squalamine in-hibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. (1998) 58:2784–2792.
   Google Scholar
• KOHLHAGEN G, PAULL KD, CUSHMAN M et al.: Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. MoL Pharmacol (1998) 54:50–58.
   PubMed Web of Science ®Google Scholar
• MOREAU P, ANIZON F, SANCELME M et al.: Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J. Med. Chem. (1998) 41:1631–1640.
   PubMedGoogle Scholar
• KIM JS, SUN Q, YU C et al: Quantitative structure-activity relationships on 5-substituted terbenzimida-zoles as topoisomerase I poisons and antitumor agents. Bioorg. Med. Chem. (1998) 6:163–172.
   PubMed Web of Science ®Google Scholar
• REDINBO MR, STEWART L, KUHN P et al.: Crystal struc-tures of human topoisomerase I in covalent and non-covalent complexes with DNA. Science (1998) 279:1504–1513.
   PubMed Web of Science ®Google Scholar
• STEWART L, REDINBO MR, QIU XY et al: A model for themechanism of human topoisomerase I. Science (1998) 279:1534–1541.
   PubMed Web of Science ®Google Scholar
• BRIDEWELL DJ, FINLAY GJ, BAGULEY BC: Differential actions of aclarubicin and doxorubicin: the role of to-poisomerase I. Oncol Res. (1997) 9:535–542.
   PubMedGoogle Scholar
• SCHMITT E, SANE AT, STEYAERT A et al.: The develop-ment of novel apoptotic drugs I: the Bc1-xL and Bax-alpha control points: modulation of apoptosis in-duced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation. Biochem. Cell Biol. (1997) 75:301–314.
   PubMedGoogle Scholar
• TOLEDO LM, LYDON NB: Structures of staurosporine bound to CDK2 and cAPK-new tools for structure-based design of protein kinase inhibitors. Structure (1997) 5:1551–1556.
   PubMedGoogle Scholar
• MICHAUD S, GOUR BJ: Cathepsin B inhibitors as poten-tial anti-metastatic agents. Exp. Opin. Ther. Patents (1998) 8:645–672.
   Web of Science ®Google Scholar
• ST CROIX B, KERBEL RS: Cell adhesion and drug resis-tance in cancer. Curr. Opin. Oncol (1997) 9:549–556.
   PubMedGoogle Scholar
• HOCHHAUSER D: Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. Anticancer Drugs (1997) 8:903–910.
   PubMed Web of Science ®Google Scholar
• YUN K: Genomic imprinting and carcinogenesis. His-tol. Histopathol (1998) 13:425–431.
   PubMedGoogle Scholar
• BARR FG: Chromosomal translocations involving paired box transcription factors in human cancer. Int. Biochem. Cell Biol. (1997) 29:1449–1461.
   PubMed Web of Science ®Google Scholar
• GARCIA R, JOVE R: Activation of STAT transcription fac-tors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. (1998) 5:79–85.
   PubMed Web of Science ®Google Scholar